Vimarsana
Biggest News Aggregation in the World

Page 24 - Andrew Baum News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Andrew Baum. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Andrew Baum Today - Breaking & Trending Today

Novartis Ag (NVS) Q3 2023 Earnings Call Transcript - Vimarsana News

Novartis Ag (NVS) Q3 2023 Earnings Call Transcript

NVS earnings call for the period ending September 30, 2023.

Source: fool.com
Eli Lilly Is Waiting for Obesity-Drug Approval. How Much It Could Be Worth. - Vimarsana News

Eli Lilly Is Waiting for Obesity-Drug Approval. How Much It Could Be Worth.

Eli Lilly’s diabetes drug Mounjaro is expected to be approved to treat obesity in the near future. It could drive sales for more than a decade.

Wall Street hikes forecasts for anti-obesity drug sales to $100 billion - Vimarsana News

Wall Street hikes forecasts for anti-obesity drug sales to $100 billion

Citi notched its estimate for incretin drug sales to $71 billion by 2035, up from its prior estimate of $55 billion. That view seems conservative. Here's why.

Source: cnbc.com
Eli Lilly and Company (NYSE:LLY) Q2 2023 Earnings Call Transcript - Vimarsana News

Eli Lilly and Company (NYSE:LLY) Q2 2023 Earnings Call Transcript

Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2023 Earnings Call. [Operator Instructions].

Eli Lilly (LLY) Q2 2023 Earnings Call Transcript - Vimarsana News

Eli Lilly (LLY) Q2 2023 Earnings Call Transcript

LLY earnings call for the period ending June 30, 2023.

Source: fool.com